Institution
University of Münster
Education•Münster, Germany•
About: University of Münster is a education organization based out in Münster, Germany. It is known for research contribution in the topics: Population & Catalysis. The organization has 35609 authors who have published 69059 publications receiving 2278534 citations. The organization is also known as: University of Munster & University of Muenster.
Topics: Population, Catalysis, Transplantation, Gene, Crystal structure
Papers published on a yearly basis
Papers
More filters
••
TL;DR: The action of the IQ motif may result in complex signaling as observed for myosins and the L‐type Ca2+ channels and is highly localized as required for sites of neuronal polarized growth and plasticity, fertilization, mitosis and cytoskeletal organization.
448 citations
••
TL;DR: This review summarizes current knowledge of interrelationships between the form and function of leaf venation and the evolution of Leaf venation patterns and refers to the topic of individual and intraspecific variation.
447 citations
••
TL;DR: An implementation of the KDIGO guidelines compared with standard care reduced the frequency and severity of AKI after cardiac surgery in high risk patients.
Abstract: PurposeCare bundles are recommended in patients at high risk for acute kidney injury (AKI), although they have not been proven to improve outcomes. We sought to establish the efficacy of an implementation of the Kidney Disease Improving Global Outcomes (KDIGO) guidelines to prevent cardiac surgery-associated AKI in high risk patients defined by renal biomarkers.MethodsIn this single-center trial, we examined the effect of a “KDIGO bundle” consisting of optimization of volume status and hemodynamics, avoidance of nephrotoxic drugs, and preventing hyperglycemia in high risk patients defined as urinary [TIMP-2]·[IGFBP7] > 0.3 undergoing cardiac surgery. The primary endpoint was the rate of AKI defined by KDIGO criteria within the first 72 h after surgery. Secondary endpoints included AKI severity, need for dialysis, length of stay, and major adverse kidney events (MAKE) at days 30, 60, and 90.ResultsAKI was significantly reduced with the intervention compared to controls [55.1 vs. 71.7%; ARR 16.6% (95 CI 5.5–27.9%); p = 0.004]. The implementation of the bundle resulted in significantly improved hemodynamic parameters at different time points (p < 0.05), less hyperglycemia (p < 0.001) and use of ACEi/ARBs (p < 0.001) compared to controls. Rates of moderate to severe AKI were also significantly reduced by the intervention compared to controls. There were no significant effects on other secondary outcomes.ConclusionAn implementation of the KDIGO guidelines compared with standard care reduced the frequency and severity of AKI after cardiac surgery in high risk patients. Adequately powered multicenter trials are warranted to examine mortality and long-term renal outcomes.
447 citations
••
01 Mar 2003-Nuclear Instruments & Methods in Physics Research Section A-accelerators Spectrometers Detectors and Associated Equipment
TL;DR: The PHENIX detector as mentioned in this paper is designed to perform a broad study of A-A, p-A and p-p collisions to investigate nuclear matter under extreme conditions, and is used to study systematic variations with species and energy as well as to measure the spin structure of the nucleon.
Abstract: The PHENIX detector is designed to perform a broad study of A-A, p-A, and p-p collisions to investigate nuclear matter under extreme conditions A wide variety of probes, sensitive to all timescales, are used to study systematic variations with species and energy as well as to measure the spin structure of the nucleon Designing for the needs of the heavy-ion and polarized-proton programs has produced a detector with unparalleled capabilities PHENIX measures electron and muon pairs, photons, and hadrons with excellent energy and momentum resolution The detector consists of a large number of subsystems that are discussed in other papers in this volume The overall design parameters of the detector are presented (C) 2002 Elsevier Science BV All rights reserved
447 citations
••
University of Paris1, Pierre-and-Marie-Curie University2, Leeds Teaching Hospitals NHS Trust3, Leiden University4, University College Dublin5, Medical University of Vienna6, University of Crete7, Ruhr University Bochum8, Charité9, University of Barcelona10, Rikshospitalet–Radiumhospitalet11, Katholieke Universiteit Leuven12, University of Leeds13, University of California, San Diego14, Maastricht University15, University of Münster16, Royal National Hospital for Rheumatic Diseases17, University of Glasgow18, University of Rochester19, University of Amsterdam20, Sapienza University of Rome21, Oregon Health & Science University22
TL;DR: These recommendations are intended to provide rheumatologists, patients and other stakeholders with a consensus on the pharmacological treatment of PsA and strategies to reach optimal outcomes, based on combining evidence and expert opinion.
Abstract: Background Psoriatic arthritis (PsA) is a clinically heterogeneous disease. Clear consensual treatment guidance focused on the musculoskeletal manifestations of PsA would be advantageous. The authors present European League Against Rheumatism (EULAR) recommendations for the treatment of PsA with systemic or local (non-topical) symptomatic and disease-modifying antirheumatic drugs (DMARD). Methods The recommendations are based on evidence from systematic literature reviews performed for non-steroidal anti-infl ammatory drugs (NSAID), glucocorticoids, synthetic DMARD and biological DMARD. This evidence was discussed, summarised and recommendations were formulated by a task force comprising 35 representatives, and providing levels of evidence, strength of recommendations and levels of agreement. Results Ten recommendations were developed for treatment from NSAID through synthetic DMARD to biological agents, accounting for articular and extraarticular manifestations of PsA. Five overarching principles and a research agenda were defi ned. Conclusion These recommendations are intended to provide rheumatologists, patients and other stakeholders with a consensus on the pharmacological treatment of PsA and strategies to reach optimal outcomes, based on combining evidence and expert opinion. The research agenda informs directions within EULAR and other communities interested in PsA.
446 citations
Authors
Showing all 36075 results
Name | H-index | Papers | Citations |
---|---|---|---|
Hyun-Chul Kim | 176 | 4076 | 183227 |
Klaus Müllen | 164 | 2125 | 140748 |
Giacomo Bruno | 158 | 1687 | 124368 |
Anders M. Dale | 156 | 823 | 133891 |
Holger J. Schünemann | 141 | 810 | 113169 |
Joachim Heinrich | 136 | 1309 | 76887 |
Markus Merschmeyer | 132 | 1188 | 84975 |
Klaus Ley | 129 | 495 | 57964 |
Robert W. Mahley | 128 | 363 | 60774 |
Robert J. Kurman | 127 | 397 | 60277 |
Bart Barlogie | 126 | 779 | 57803 |
Thomas Schwarz | 123 | 701 | 54560 |
Carlos Caldas | 122 | 547 | 73840 |
Klaus Weber | 121 | 524 | 60346 |
Andrey L. Rogach | 117 | 576 | 46820 |